Showing 2811 results
-
Press release /Dear SMA Community, Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen…
-
Press release /AveXis announces Page Bouchard, DVM has been appointed Senior Vice President of Research and Chief Scientific Officer, effective August 5, 2019. Dr. Bouchard is a 27-year industry veteran with…
-
Press release /Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)—the first and only self-administered, targeted B-cell therapy for…
-
Press release /New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated…
-
Press release /Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the…
-
Press release /In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1…
-
Press release /First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access…
-
Press release /Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal…
-
Press release /COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1 Adjuvant…
-
Press release /In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a…